Ein vorhandenes Transplantationsmittel verlangsamt das Fortschreiten des Typ -1 -Diabetes bei neu diagnostizierten jungen Menschen, was die erste Therapie ebnet, die die Krankheit nach der Diagnose verändert. ATG kann selbst bei einer relativ geringen Dosis bei jungen Menschen, bei denen der Typ-1-Diabetes neu diagnostiziert wurde, verlangsamen.

I’ve linked to the news release in the post above. In this comment, for those interested, here’s the link to the peer reviewed journal article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01674-5/abstract

From the linked article:

Existing drug slows progression of type 1 diabetes in newly diagnosed

**An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis**.

A new study led by researchers from UZ Leuven, Belgium’s largest university hospital, tested whether a drug called antithymocyte globulin (ATG), an existing immune-suppressing drug, could preserve beta cell function in young people who had just been diagnosed with diabetes.

Ordinarily, ATG is used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs.

The findings are promising, showing that **ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes**. The lower dose also caused fewer side effects, making it a more practical option.